21
IRUS Total
Downloads

Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)

File Description SizeFormat 
s41416-021-01662-w.pdfPublished version1.05 MBAdobe PDFView/Open
Title: Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)
Authors: Fotopoulou, C
Rockall, A
Lu, H
Lee, P
Avesani, G
Russo, L
Petta, F
Ataseven, B
Waltering, K-U
Koch, JA
Crum, WR
Cunnea, P
Heitz, F
Harter, P
Aboagye, EO
Du Bois, A
Prader, S
Item Type: Journal Article
Abstract: Background Predictive models based on radiomics features are novel, highly promising approaches for gynaecological oncology. Here, we wish to assess the prognostic value of the newly discovered Radiomic Prognostic Vector (RPV) in an independent cohort of high-grade serous ovarian cancer (HGSOC) patients, treated within a Centre of Excellence, thus avoiding any bias in treatment quality. Methods RPV was calculated using standardised algorithms following segmentation of routine preoperative imaging of patients (n = 323) who underwent upfront debulking surgery (01/2011-07/2018). RPV was correlated with operability, survival and adjusted for well-established prognostic factors (age, postoperative residual disease, stage), and compared to previous validation models. Results The distribution of low, medium and high RPV scores was 54.2% (n = 175), 33.4% (n = 108) and 12.4% (n = 40) across the cohort, respectively. High RPV scores independently associated with significantly worse progression-free survival (PFS) (HR = 1.69; 95% CI:1.06–2.71; P = 0.038), even after adjusting for stage, age, performance status and residual disease. Moreover, lower RPV was significantly associated with total macroscopic tumour clearance (OR = 2.02; 95% CI:1.56–2.62; P = 0.00647). Conclusions RPV was validated to independently identify those HGSOC patients who will not be operated tumour-free in an optimal setting, and those who will relapse early despite complete tumour clearance upfront. Further prospective, multicentre trials with a translational aspect are warranted for the incorporation of this radiomics approach into clinical routine.
Issue Date: 18-Dec-2021
Date of Acceptance: 1-Dec-2021
URI: http://hdl.handle.net/10044/1/93667
DOI: 10.1038/s41416-021-01662-w
ISSN: 0007-0920
Publisher: Springer Nature [academic journals on nature.com]
Start Page: 1047
End Page: 1054
Journal / Book Title: British Journal of Cancer
Volume: 126
Copyright Statement: © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Sponsor/Funder: Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Medical Research Council
Funder's Grant Number: RDC04 79560
RDC04 79560
RDC04
RDC04
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
BEVACIZUMAB
TRIAL
Humans
Neoplasm Recurrence, Local
Neoplasm, Residual
Ovarian Neoplasms
Prognosis
Retrospective Studies
Humans
Ovarian Neoplasms
Neoplasm Recurrence, Local
Neoplasm, Residual
Prognosis
Retrospective Studies
Science & Technology
Life Sciences & Biomedicine
Oncology
BEVACIZUMAB
TRIAL
Oncology & Carcinogenesis
1112 Oncology and Carcinogenesis
1117 Public Health and Health Services
Publication Status: Published
Open Access location: https://www.nature.com/articles/s41416-021-01662-w
Online Publication Date: 2021-12-18
Appears in Collections:Department of Surgery and Cancer
Faculty of Medicine



This item is licensed under a Creative Commons License Creative Commons